Live from ASH 2024 | Oral Report Features Encouraging Data of Ascentage Pharma's Bcl-2 Inhibitor Lisaftoclax in R/R MM, Including a Median PFS Over 9 Months
ROCKVILLE, Md. and SUZHOU, China, Dec. 10, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for...
MinIO Research Reveals the Impact of AI on Storage Infrastructure
IT leaders see object storage as the foundation for AI and advanced analytic workloads REDWOOD CITY, Calif., Dec. 10, 2024 /PRNewswire/ -- MinIO, the leader in high-performance object storage, today announced the findings of its Object Storage and...
Live from ASH 2024 | Ascentage Pharma's Bcl-2 Inhibitor Lisaftoclax in Combinations Demonstrates Potential Clinical Benefit in Patients with Prior Exposure to Venetoclax
ROCKVILLE, Md. and SUZHOU, China, Dec. 10, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for...
Live from ASH 2024 | First Dataset of Olverembatinib as Second-Line Therapy in Patients with Non-T315I-Mutant CP-CML Presented in Oral Report
ROCKVILLE, Md. and SUZHOU, China, Dec. 10, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for...
Live from ASH 2024 | 1.5-Year Follow-Up Data from a Global Study of Olverembatinib Reaffirms Potential in Overcoming Resistance/Intolerance to Ponatinib or Asciminib
ROCKVILLE, Md. and SUZHOU, China, Dec. 10, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for...
Live from ASH 2024 | First Dataset of Olverembatinib in Combination with Bcl-2 Inhibitor Lisaftoclax Demonstrates Potential Clinical Benefits as a Chemotherapy-Free Regimen for Children with R/R Ph+ ALL
ROCKVILLE, Md. and SUZHOU, China, Dec. 10, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for...
AQUASTRONG Unveils Comprehensive Pool Circulation System Solutions: From Filtration to Heating
HONG KONG, Dec. 10, 2024 /PRNewswire/ -- AQUASTRONG today announced the launch of its upgraded pool circulation system solutions, further expanding its product line to meet the diverse needs of pool users. Leveraging innovative technology and an...
Vodafone Idea selects Tejas Networks to scale its backhaul capacity for 4G and 5G rollouts
BENGALURU, India, Dec. 10, 2024 /PRNewswire/ -- Tejas Networks (BSE: 540595) (NSE: TEJASNET) today announced that it has entered into a three - year contract with Vodafone Idea Limited ("VIL"), a leading telecom service provider in India, to supply...
KONJAKUSO by Funbound Co., Ltd. Now Offers Luxury and Premium Rental Properties on Homes & Villas by Marriott Bonvoy
YASU and OSAKA, Japan, Dec. 10, 2024 /PRNewswire/ -- Funbound Co., Ltd., a company that specializes in the renovation of vacant houses and buildings into high-end private lodgings under the KONJAKUSO brand, announced that select rental properties...
Antengene Presents Results from Two Late-Stage Clinical Studies of Selinexor at ASH 2024
SHANGHAI and HONG KONG, Dec. 10, 2024 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing...